Gene · 10733
Papers2,106
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,106
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| 17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications. | Cancers (Basel) | 2024 | 38254827 | PubTator, text mining | PubMed |
| E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma. | Medicine (Baltimore) | 2024 | 38241554 | PubTator, text mining | PubMed |
| Novel Variants of CEP152 in a Case of Compound-Heterozygous Inheritance of Epilepsy. | Glob Med Genet | 2024 | 38229970 | PubTator, text mining | PubMed |
| Therapeutic Approaches to Targeting Androgen Receptor Splice Variants. | Cells | 2024 | 38201308 | PubTator, text mining | PubMed |
| Therapeutic potential of targeting polo-like kinase 4. | Eur J Med Chem | 2024 | 38199166 | PubTator, text mining | PubMed |
| Cadmium promotes the binding and centrosomal translocation of CCDC85C and PLK4 via ROS-GCLM pathway to trigger centrosome amplification in colon cancer cells. | Toxicol Lett | 2024 | 38185225 | PubTator, text mining | PubMed |
| Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells. | Redox Biol | 2024 | 38184997 | PubTator, text mining | PubMed |
| LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma. | Cell Death Dis | 2024 | 38177154 | PubTator, text mining | PubMed |
| Pinpointing top inhibitors for GSK3β from pool of indirubin derivatives using rigorous computational workflow and their validation using molecular dynamics (MD) simulations. | Sci Rep | 2024 | 38168595 | PubTator, text mining | PubMed |
| Different evolution of S. aureus methicillin-resistant and methicillin-susceptible infections, Argentina. | Heliyon | 2024 | 38163174 | PubTator, text mining | PubMed |
| Bi-allelic variants in CEP295 cause Seckel-like syndrome presenting with primary microcephaly, developmental delay, intellectual disability, short stature, craniofacial and digital abnormalities. | EBioMedicine | 2024 | 38154379 | PubTator, text mining | PubMed |
| Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer. | Cancer Commun (Lond) | 2024 | 38140698 | PubTator, text mining | PubMed |
| Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. | Leukemia | 2024 | 38114624 | PubTator, text mining | PubMed |
| Correction: PLK4 self-phosphorylation drives the selection of a single site for procentriole assembly. | J Cell Biol | 2024 | 38095873 | PubTator, text mining | PubMed |
| Uncovering the non-histone interactome of the BRPF1 bromodomain using site-specific azide-acetyllysine photochemistry. | J Biol Chem | 2024 | 38072045 | PubTator, text mining | PubMed |
| Formation and function of multiciliated cells. | J Cell Biol | 2024 | 38032388 | PubTator, text mining | PubMed |
| PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma. | Endocr Connect | 2024 | 37992487 | PubTator, text mining | PubMed |
| Mosaic variegated aneuploidy syndrome with tetraploid, and predisposition to male infertility triggered by mutant CEP192. | HGG Adv | 2024 | 37981762 | PubTator, text mining | PubMed |
| Polo-Like Kinase 4 Correlates with Aggressive Tumor Characteristics, Shortened Disease-Free Survival and Overall Survival in Patients with Cutaneous Melanoma who Undergo Surgical Resection. | Tohoku J Exp Med | 2024 | 37940564 | PubTator, text mining | PubMed |
| Deleterious genetic changes in AGTPBP1 result in teratozoospermia with sperm head and flagella defects. | J Cell Mol Med | 2024 | 37937809 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10733/papers?page=7